Mulhall Brian P, Younossi Zobair M
Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA.
Curr Treat Options Gastroenterol. 2004 Dec;7(6):423-430. doi: 10.1007/s11938-004-0001-9.
Nonalcoholic steatohepatitis (NASH) is an important medical condition and there is great public health concern related to its increasing incidence and potential implications for the development of end-stage liver disease. NASH represents a progression beyond simple lipid deposition in the liver parenchyma, requiring histologic evidence for hepatocyte injury such as ballooning degeneration, Mallory bodies, and/or pericellular fibrosis that can potentially lead to progressive liver injury and eventually cirrhosis. It is believed that several insults contribute to the evolution of hepatic injury such as insulin dysregulation, lipid deposition, oxidative free radicals, and lipid perioxidation. Initial treatment protocols for NASH focus on various aspects of injury in an attempt to control insulin imbalances, improve lipid regulation, reduce free radicals, and ameliorate the inflammatory process. No therapy is conclusively beneficial in all individuals, but preliminary data suggest several approaches that hold promise.
非酒精性脂肪性肝炎（NASH）是一种重要的医学病症，其发病率不断上升以及对终末期肝病发展的潜在影响引发了极大的公共卫生关注。NASH代表了肝脏实质内单纯脂质沉积之外的一种进展，需要有肝细胞损伤的组织学证据，如气球样变性、马洛里小体和/或细胞周围纤维化，这些可能导致进行性肝损伤并最终发展为肝硬化。据信，多种损伤因素促成了肝损伤的演变，如胰岛素调节异常、脂质沉积、氧化自由基和脂质过氧化。NASH的初始治疗方案侧重于损伤的各个方面，试图控制胰岛素失衡、改善脂质调节、减少自由基并减轻炎症过程。没有一种疗法对所有个体都有确凿的益处，但初步数据表明有几种方法具有前景。
